Published in
American Society of Hematology, Blood, 10(132), p. 1050-1063
DOI: 10.1182/blood-2018-03-836601
Links
Tools
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92
Journal article published in 2018 by
Eugenio Morelli 
,
Lavinia Biamonte,
Cinzia Federico,
Nicola Amodio,
Maria Teresa Di Martino ,
Maria Eugenia Gallo Cantafio,
Martina Manzoni ,
Francesca Scionti,
Mehmet Kemal Samur,
Annamaria Gullà,
Maria Angelica Stamato,
Maria Rita Pitari,
Daniele Caracciolo,
Settimio Sesti,
Niels M. Frandsen
and other authors.
,
Lavinia Biamonte,
Cinzia Federico,
Nicola Amodio,
Maria Teresa Di Martino ,
Maria Eugenia Gallo Cantafio,
Martina Manzoni ,
Francesca Scionti,
Mehmet Kemal Samur,
Annamaria Gullà,
Maria Angelica Stamato,
Maria Rita Pitari,
Daniele Caracciolo,
Settimio Sesti,
Niels M. Frandsen
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points First-in-class MIR17PTi enables 1-shot downregulation of miR-17-92 in vitro and in vivo, with favorable pharmacokinetic profile. MIR17PTi affects homeostatic MYC/miR-17-92 FFLs in MM cells, resulting in strong anti-MM activity.